Abstracts tagged "Lung Disease"

Abstract Number: 2462 • 2018 ACR/ARHP Annual Meeting
Efficacy and Safety in the Middle-LONG Period of Rituximab in the Treatment of Diffuse Interstitial Pulmonary Disease Associated with Rheumatoid Arthritis
Francisco Javier Narváez¹, Alejandro Robles Perez², Patricio Luburich³, J Alegre⁴, Milagros Ricse⁵, Carmen Gomez Vaquero⁶, Joan Miquel Nolla⁵ and Maria Molina⁵, ¹Rheumatology Department, Hospital de Bellvitge. Barcelona. Spain, L’Hospitalet de Llobregat, Spain, ²Pneumology, Hospital Universitario de Bellvitge, Barcelona, Spain, ³Radiology, Hospital Universitario de Bellvitge, Barcelona, Spain, ⁴Rheumatology, Hospital Universitario Doctor Peset. Valencia. Spain, Valencia, Spain, ⁵Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ⁶Rheumatology Department, Hospital Universitario de Bellvitge, Idibell, Barcelona, Spain
Background/Purpose: To evaluate the efficacy and safety of rituximab (RTX) in the medium- to long-term for the management of progressive rheumatoid arthritis–related interstitial lung disease…
Abstract Number: 2919 • 2018 ACR/ARHP Annual Meeting
An Epidemic: Severe Lung Disease in Patients with Systemic Juvenile Idiopathic Arthritis, Risk Factors and Predictors
Shima Yasin¹, Christopher Towe^2,3, Ndate Fall⁴, Alexei Grom^3,4 and Grant Schulert^1,5, ¹Rheumatology, Divisions of Rheumatology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ²Pulmonology, Division of Pulmonology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ³Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, ⁴Division of Rheumatology, Divisions of Rheumatology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ⁵Pediatrics, Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH
Background/Purpose: There is growing awareness of severe and often fatal chronic lung disease in patients with systemic juvenile idiopathic arthritis (sJIA). However, clinical features and…
Abstract Number: 2974 • 2018 ACR/ARHP Annual Meeting
Long-Term Survival in Lung Transplantation for Interstitial Lung Disease Due to Rheumatic Systemic Diseases. Study of 26 Cases of a Single Center
Diana Prieto Peña¹, Amaya Martinez Meñaca², Monica Calderón Goercke¹, José Luis Martín-Varillas³, Belén Atienza-Mateo³, Victor Manuel Mora Cuesta², Sonia Fernandez Rozas⁴, David Iturbe Fernandez⁴, Carmen González-Vela⁵, Jose Manuel Cifrian Martinez⁴, Miguel Angel González-Gay⁶ and Ricardo Blanco³, ¹Rheumatology, Rheumatology. Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ²Neumology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, SANTANDER, Spain, ³Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ⁴Neumology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ⁵Pathology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ⁶School of Medicine, University of Cantabria, Santander, Spain, Santander, Spain
Background/Purpose: Interstitial lung disease (ILD) is one of the most serious complications associated with rheumatic systemic diseases. Patients with ILD have increased mortality and limited…
Abstract Number: 2688 • 2017 ACR/ARHP Annual Meeting
Collagen Metabolite Biomarker Levels Are Associated with the Amount of Fibrosis in Internal Organs in Systemic Sclerosis Patients
Anne Sofie Siebuhr¹, Satoshi Kubo², Pernille Juhl³, K Nakano⁴, S Nakayamada⁵, Morten Karsdal⁶, Anne-C. Bay-Jensen⁷ and Yoshiya Tanaka⁸, ¹the first department of internal medicine, University of occupational and environmental health, Fukuoka, Japan, ²The first department of internal medicine, University of Occupational en environmental Health, Fukuoka, Japan, ³Nordic Bioscience, Herlev, Denmark, ⁴the first department of internal medicin, University of occupational and environmental health, fukuoka, Japan, ⁵The first department of internal medicine, University of Occupational and environmental Health, fukuoka, Japan, ⁶Biomarkers and Reseacrh, Nordic Bioscience, Herlev, Denmark, ⁷Biomarkers and Reseach, Nordic Bioscience, Herlev, Denmark, ⁸The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan
Background/Purpose: Biomarkers that can monitor the fibrotic burden will aid in trial enrichment and personalized health care in SSc. SSc is associated with internal organ…
Abstract Number: 2737 • 2017 ACR/ARHP Annual Meeting
Pulmonary Manifestations of Primary Systemic Vasculitides
Jean-Paul Makhzoum¹, Raashid Luqmani², Richard A. Watts³, Anthea Craven⁴, Peter A. Merkel⁵ and Christian Pagnoux⁶, ¹Rheumatology, Vasculitis Clinic, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ²Botnar Research Centre, University of Oxford, Oxford, United Kingdom, ³Rheumatology Department, The Ipswich Hospital, Ipswich, Great Britain, ⁴Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, Oxford University Hospitals, Oxford, United Kingdom, ⁵Division of Rheumatology, University of Pennsylvania; Perelman School of Medicine, Philadelphia, PA, ⁶Rheumatology-Vasculitis clinic, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada
Background/Purpose: Pulmonary involvement in systemic primary vasculitides is diverse and occurs with variable incidence depending on the type of vasculitis. This study aimed to describe…
Abstract Number: 2776 • 2017 ACR/ARHP Annual Meeting
Plasmacytoid Dendritic Cells in Systemic Fibrosis: Pathogenic Role in Bleomycin-Induced Fibrosis Model and Correlation with Disease in Patients with Systemic Sclerosis
Suzanne Kafaja¹, Isela Valera², Anagha Divekar³, Rajan Saggar⁴, Dinesh Khanna⁵, Daniel E. Furst⁶ and Ram R. Singh⁷, ¹Department of Internal Medicine, University of California Los Angeles, David Geffen School of Medicine, Division of Rheumatology, Los Angeles, CA, ²Autoimmunity and Tolerance Laboratory, Division of Rheumatology, Department of Medicine, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, ³Biolegend, Sa Diego, CA, ⁴Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁵University of Michigan, Ann Arbor, MI, ⁶David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁷Autoimmunity and Tolerance Laboratory, Department of Medicine/Rheumatology, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA
Background/Purpose: Fibrosis is the end-result of most inflammatory conditions, but its pathogenesis remains unclear. Studies in patients and animal models suggest a role for T-cells…
Abstract Number: 24 • 2017 ACR/ARHP Annual Meeting
Trafficking of Innate B Cells to the Lungs As a Novel Mechanism in a Model of Pulmonary Lupus and Vasculitis
Priti Prasad¹, Michael Fishbein², Rohan Sharma³, Ramesh Halder⁴, Isela Valera¹ and Ram R. Singh⁵, ¹Autoimmunity and Tolerance Laboratory, Division of Rheumatology, Department of Medicine, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, ²Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at University of California Los Angeles, Los ángeles, CA, ³Autoimmunity and Tolerance Laboratory, Division of Rheumatology, Department of Medicine, David Geffen School of Medicine at University of California Los Angeles, Los angeles, CA, ⁴Autoimmunity and Tolerance Laboratory, Division of Rheumatology, Department of Medicine, David Geffen School of Medicine at University of California Los Angeles, Los ángeles, CA, ⁵Autoimmunity and Tolerance Laboratory, Department of Medicine/Rheumatology, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA
Background/Purpose: Lung is involved in up to 50% patients with SLE. Among manifestations of pulmonary lupus, pneumonitis, vasculitis and diffuse pulmonary hemorrhage (DPH) carry a…
Abstract Number: 257 • 2017 ACR/ARHP Annual Meeting
The Use of Positron Emission Tomography (PET)-Scan for the Quantitative Assessment of Interstitial Lung Disease in Systemic Sclerosis
Daphne Peelen¹, Ben Zwezerijnen², Esther Nossent¹, Lilian Meijboom¹, Otto Hoekstra³, Conny van der Laken⁴ and Alexandre Voskuyl⁴, ¹VUmc, Amsterdam, Netherlands, ²Nuclear Medicine, VUmc, Amsterdam, Netherlands, ³Department of Radiology & Nuclear Medicine, VU University Medical Center, Amsterdam, The Netherlands, Amsterdam, Netherlands, ⁴Department of Rheumatology, Amsterdam Rheumatology and immunology Center - location VU University Medical Center, Amsterdam, The Netherlands, Amsterdam, Netherlands
Background/Purpose: Interstitial lung disease (ILD) in systemic sclerosis is treated by immunosuppressive drugs (e.g. cyclophosphamide), aimed at reduction of inflammatory response . Differentiation between inflamed…
Abstract Number: 400 • 2017 ACR/ARHP Annual Meeting
Combination of the Collagen-Induced Arthritis and Organic Dust-Induced Airway Inflammation Models As a Model of Interstitial Lung Disease in Rheumatoid Arthritis
Katherine Janike¹, Jill Poole¹, Geoffrey M. Thiele², Michael J. Duryee³, Lynell W. Klassen⁴, Amy Nelson⁵, Kristi Warren⁶, Benjamin Swanson⁷ and Ted R. Mikuls⁸, ¹Medicine, University of Nebraska Medical Center, Omaha, NE, ²Int Med/Sec of Rheum/Immun, Univ of NE Medical Ctr, Omaha, NE, ³Internal Medicine Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁴Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ⁵Department of Medicine, University of Nebrasa Medical Center, Omaha, NE, ⁶Department of Medicine, University of Nebraska Medical Center, Omaha, NE, ⁷Department of Pathology, University of Nebraska Medical Center, Omaha, NE, ⁸Internal Medicine, Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Rheumatoid Arthritis (RA) is characterized by extra-articular involvement including interstitial/inflammatory lung disease (ILD). Whereas the coexistence of RA and ILD is known, mechanisms…
Abstract Number: 568 • 2017 ACR/ARHP Annual Meeting
Complement Consumption As a Predictor of Pulmonary Manifestation in Patients with Primary Sjögren’s Syndrome: Results from a Unicentric Observational Study
Alisson Pugliesi¹, RACHEL ZERBINI MARIANO², Raquel Baldini Campos³, Simone Appenzeller⁴, Manoel Bertolo⁵ and ZORAIDA SACHETTO¹, ¹INTERNAL MEDICINE, DISCIPLINE OF RHEUMATOLOGY, Faculty of Medical Sciences, State University of Campinas (UNICAMP), CAMPINAS, Brazil, ²Radiology and Diagnostic Imaging, Faculty of Medical Sciences, State University of Campinas (UNICAMP), CAMPINAS, Brazil, ³Internal Medicine, Faculty of Medical Sciences, State University of Campinas (UNICAMP), CAMPINAS, Brazil, ⁴Pediatric Rheumatology Unit, State University of Campinas, Campinas, Brazil, ⁵INTERNAL MEDICINE, DISCIPLINE OF RHEUMATOLOGY, Faculty of Medical Sciences, State University of Campinas (UNICAMP), Campinas, Brazil
Complement Consumption as a Predictor of Pulmonary Manifestation in Patients with Primary Sjögren’s Syndrome: Results from a Unicentric Observational StudyBackground/Purpose: Primary Sjögren’s syndrome (pSS) may…
Abstract Number: 838 • 2017 ACR/ARHP Annual Meeting
Rates of New-Onset Pulmonary Disease Among Patients with Systemic Lupus Erythematosus in Sweden
Lindsy J. Forbess¹, Michael Weisman² and Julia F Simard³, ¹Medicine, Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ²Cedars-Sinai Medical Center Division of Rheumatology, Los Angeles, CA, ³Division of Epidemiology, Health Research and Policy Department, Stanford School of Medicine, Stanford, CA
Background/Purpose: Our goal was to examine lung disease and types of pulmonary manifestations observed in patients with SLE. We studied population-based register data from Sweden…
Abstract Number: 854 • 2017 ACR/ARHP Annual Meeting
Predictive Modeling of Mortality in Polymyositis/Dermatomyositis Patients with Interstitial Lung Disease Based on Combination of Serum Myositis-Specific Autoantibodies and Conventional Biomarkers
Takahisa Gono¹, Kenichi Masui², Yasushi Kawaguchi³, Kei Ikeda⁴, Atsushi Kawakami⁵, Maasa Tamura⁶, Yoshinori Tanino⁷, Takahiro Nunokawa⁸, Yuko Kaneko⁹, Shinji Sato¹⁰, Katsuaki Asakawa¹¹, Naoshi Nishina⁹ and Masataka Kuwana¹, ¹Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ²Department of Anesthesiology, National Defense Medical College School of Medicine, Tokorozawa, Japan, ³Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ⁴Department of Allergy and Clinical Immunology, Chiba University Hospital, Chiba, Japan, ⁵Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki City, Japan, ⁶Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan, ⁷Department of Pulmonary Medicine, Fukushima Medical University School of Medicine, Fukushima, Japan, ⁸Department of Rheumatic Diseases, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan, ⁹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ¹⁰Division of Rheumatology, Department of Internal Medicine, Tokai University School of Medicine, Isehara, Japan, ¹¹Division of Respiratory Medicine, Niigata University Medical and Dental Hospital, Niigata, Japan
Background/Purpose: Interstitial lung disease (ILD) is one of the leading causes of mortality in patients with polymyositis or dermatomyositis (PM/DM). Since clinical courses and outcomes…
Abstract Number: 939 • 2017 ACR/ARHP Annual Meeting
Stimulator of Interferon Genes (STING)-Induced Endothelial-Mesenchymal Transition (EndMT) Contributes to Interstitial Lung Disease in Sting-Associated Vasculopathy with Onset in Infancy (SAVI) Patients
Louise Malle¹, Dan Yang², Adriana Almeida de Jesus¹, Guibin Chen², Bernadette Marrero¹, Gina A. Montealegre Sanchez¹, Yin Liu³, Gregor Dueckers⁴, Suzanne Ramsey⁵, Joseph Fontana⁶, Rachel VanTries¹, Yan Huang¹, Laisa Santiago⁷, Benito Gonzalez⁸, Paul Brogan⁹, Juergen Brunner¹⁰, Ebun Omoyinmi¹¹, Athimalaipet V. Ramanan¹², Amy Paller¹³, Olcay Y. Jones¹⁴, Seza Ozen¹⁵, Stephen R. Brooks¹⁶, Manfred Boehm¹⁷ and Raphaela Goldbach-Mansky¹, ¹Translational Autoinflammatory Disease Studies (TADS), Laboratory of Clinical Investigation and Microbiology (LCIM), NIAID/NIH, Bethesda, MD, ²Center for Molecular Medicine, NHLBI/NIH, Bethesda, MD, ³Scientific Review Branch, NIAMS/NIH, Bethesda, MD, ⁴Helios Kliniken - Kinderklinik, HELIOS Klinikum Krefeld, Krefeld, Germany, ⁵Pediatric Rheumatology, IWK Health Centre, Dalhousie University, Halifax, NS, Canada, ⁶Cardiovascular and Pulmonary Branch, NHLBI/NIH, Bethesda, MD, ⁷Johns Hopkins All Children's Hospital Rheumatology, Saint Petersburg, FL, ⁸Luis Calvo Mackenna Hospital, Santiago, Chile, ⁹Infection Inflammation and Rheumatology, UCL Institute of Child Health, and Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom, ¹⁰Division of Pediatric Rheumatology, Medical University Innsbruck, Innsbruck, Austria, ¹¹University College London Institute of Child Health, London, United Kingdom, ¹²Bristol Royal Hospital for Children, Bristol, United Kingdom, ¹³Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, IN, ¹⁴Department of Pediatrics, Walter Reed National Military Medical Center, Bethesda, MD, ¹⁵Department of Pediatrics, Division of Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, ¹⁶Biodata Mining and Discovery Section, Office of Science and Technology, NIAMS/NIH, Bethesda, MD, ¹⁷Center for Molecular Medicine, NHLBI/ NIH, Bethesda, MD
Background/Purpose: Pulmonary fibrosis, is a life-threatening complication of the monogenic autoinflammatory interferonopathy, STING-Associated Vasculopathy with onset in Infancy (SAVI) that is caused by gain-of-function mutations…
Abstract Number: 1486 • 2017 ACR/ARHP Annual Meeting
Interstitial Lung Disease in Primary Sjögren’s Syndrome : Clinical Presentation, Serological Biomarkers and Long Term Outcome
Chiara Baldini¹, Ilaria Puxeddu², Martina Orlandi³, Francesco Ferro⁴, Elena Elefante⁴, Nicoletta Luciano⁴, Marco Matucci-Cerinic³, Paola Migliorini² and Marta Mosca⁴, ¹Internal Medicine, Rheumatology Unit, University of Pisa, Pisa, Italy, ²Allergology and Clinical Immunology Unit, University of Pisa, Pisa, Italy, ³Rheumatology Unit, University of Florence, Florence, Italy, ⁴Rheumatology Unit, University of Pisa, Pisa, Italy
Background/Purpose: Interstitial lung disease (ILD) is a rare but potentially severe manifestation of primary Sjögren’s syndrome (pSS). The aims of this study were to: 1)…
Abstract Number: 1488 • 2017 ACR/ARHP Annual Meeting
Correlation between Lung Ultrasound, HRCT Findings and Pulmonary Function Tests in Primary Sjögren’s Syndrome (pSS)-Associated Interstitial Lung Disease
Francesco Ferro¹, Alessandra Bulleri², Andrea Delle Sedie¹, Simone Barsotti¹, Nicoletta Luciano¹, Elisa Cioffi³, Elena Elefante¹, Gianfranco Puppo⁴, Marta Mosca¹ and Chiara Baldini⁵, ¹Rheumatology Unit, University of Pisa, Pisa, Italy, ²Radiology Unit, University of Pisa, Pisa, Italy, ³Rheumatology Unit, Rheumatology Unit, University of Pisa, Pisa, Italy, ⁴Pneumology Unit, University of Pisa, Pisa, Italy, ⁵Internal Medicine, Rheumatology Unit, University of Pisa, Pisa, Italy
Background/Purpose: Recently, pleural irregularity (PI), a new lung ultrasound (US) sign, has been proposed as an emerging tool for the diagnosis of interstitial lung disease…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].